<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34314050</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>93</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>12</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 R.1 lineage variants that prevailed in Tokyo in March 2021.</ArticleTitle><Pagination><MedlinePgn>6833-6836</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.27240</ELocationID><Abstract><AbstractText>The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, such as B.1.1.7 and B.1.351, has become a crucial issue worldwide. Therefore, we began testing all patients with COVID-19 for the N501Y and E484K mutations by using polymerase chain reaction (PCR)-based methods. Nasopharyngeal swab samples from 108 patients who visited our hospital between February and April 2021 were analyzed. The samples were analyzed using reverse transcription-PCR with melting curve analysis to detect the N501Y and E484K mutations. A part of the samples was also subjected to whole-genome sequencing (WGS). Clinical parameters such as mortality and admission to the intensive care unit were analyzed to examine the association between increased disease severity and the E484K mutation. The ratio of cases showing the 501N + 484K mutation rapidly increased from 8% in February to 46% in March. WGS revealed that the viruses with 501N + 484K mutation are R.1 lineage variants. Evidence of increased disease severity related to the R.1 variants was not found. We found that the R.1 lineage variants rapidly prevailed in Tokyo in March 2021, which suggests the increased transmissibility of R.1 variants, while they showed no increased severity.</AbstractText><CopyrightInformation>© 2021 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nagano</LastName><ForeName>Katsutoshi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinical Laboratory, Tokyo Medical and Dental University (TMDU) Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tani-Sassa</LastName><ForeName>Chihiro</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinical Laboratory, Tokyo Medical and Dental University (TMDU) Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwasaki</LastName><ForeName>Yumi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Clinical Laboratory, Tokyo Medical and Dental University (TMDU) Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takatsuki</LastName><ForeName>Yuna</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Clinical Laboratory, Tokyo Medical and Dental University (TMDU) Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuasa</LastName><ForeName>Sonoka</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Laboratory, Tokyo Medical and Dental University (TMDU) Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Yuta</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Clinical Laboratory, Tokyo Medical and Dental University (TMDU) Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakajima</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical Laboratory, Tokyo Medical and Dental University (TMDU) Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sonobe</LastName><ForeName>Kazunari</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinical Laboratory, Tokyo Medical and Dental University (TMDU) Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ichimura</LastName><ForeName>Naoya</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Laboratory, Tokyo Medical and Dental University (TMDU) Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nukui</LastName><ForeName>Yoko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Infection Control and Prevention, Tokyo Medical and Dental University (TMDU) Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takeuchi</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-5689-9858</Identifier><AffiliationInfo><Affiliation>Department of Molecular Virology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanimoto</LastName><ForeName>Kousuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Genome Laboratory, Medical Research Institute, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Core, Institute of Research, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Yukie</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Research Core, Institute of Research, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>Akinori</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Research, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tohda</LastName><ForeName>Shuji</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-2642-5459</Identifier><AffiliationInfo><Affiliation>Clinical Laboratory, Tokyo Medical and Dental University (TMDU) Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>JST-CREST</Agency><Country/></Grant><Grant><Agency>Japan Agency for Medical Research and Development</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014041" MajorTopicYN="N" Type="Geographic">Tokyo</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073336" MajorTopicYN="N">Whole Genome Sequencing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">E484K variant</Keyword><Keyword MajorTopicYN="Y">R.1 lineage</Keyword><Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword><Keyword MajorTopicYN="Y">melting curve analysis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>05</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>07</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>27</Day><Hour>12</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34314050</ArticleId><ArticleId IdType="doi">10.1002/jmv.27240</ArticleId><ArticleId IdType="pmc">PMC8426954</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Volz E, Mishra S, Chand M, et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021;593:266-269.</Citation></Reference><Reference><Citation>Davies NG, Jarvis CI, CMMID COVID-19 Working Group, et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 2021;593:270-274.</Citation></Reference><Reference><Citation>Cele S, Gazy I, Jackson L, et al. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature. 2021;593:142-146.</Citation></Reference><Reference><Citation>Martins AF, Zavascki AP, Wink PL, et al. Detection of SARS-CoV-2 lineage P.1 in patients from a region with exponentially increasing hospitalisation rate, February 2021, Rio Grande do Sul, Southern Brazil. Euro Surveill. 2021;6:2100276.</Citation></Reference><Reference><Citation>PANGO lineages database. Accessed May 20, 2021. https://cov-lineages.org/lineages/lineage_R.1.html</Citation></Reference><Reference><Citation>Tokyo Metropolitan Institute of Public Health. Accessed May 20, 2021. http://www.tokyo-eiken.go.jp/lb_virus/sars2ngstree/</Citation></Reference><Reference><Citation>Garcia-Beltran WF, Lam EC St, Denis K, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184:2372-2383</Citation></Reference><Reference><Citation>Cavanaugh AM, Fortier S, Lewis P, et al. COVID-19 outbreak associated with a SARS-CoV-2 R.1 lineage variant in a skilled nursing facility after vaccination program-Kentucky, March 2021. MMWR Morb Mortal Wkly Rep. 2021;70:639-643.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>